Indirect Treatment Comparison of Blinatumomab vs. Inotuzumab Ozogamicin in R/R Acute Lymphoblastic Leukemia

Aggressive type of leukemia - R/R Ph- B-precursor ALL prognosis poor. Blinatumomab and InO are treatment options, but no direct comparison trials available. Objective of this study was to indirectly compare efficacy of blinatumomab vs. InO in adult patients with R/R ALL who had received zero or one

0 views • 21 slides